.jpg)
Amgen wins key rare disease nod for Uplizna, checking off one goal in expansion push
Uplizna is now the first FDA-approved treatment for immunoglobulin G4-related disease, a rare chronic inflammatory condition that widens the patient pool for the former Horizon Therapeutics drug.
Uplizna is now the first FDA-approved treatment for immunoglobulin G4-related disease, a rare chronic inflammatory condition that widens the patient pool for the former Horizon Therapeutics drug.
